JPH045214A - Cosmetic and drug for external use containing ascorbic acid derivative - Google Patents
Cosmetic and drug for external use containing ascorbic acid derivativeInfo
- Publication number
- JPH045214A JPH045214A JP10592190A JP10592190A JPH045214A JP H045214 A JPH045214 A JP H045214A JP 10592190 A JP10592190 A JP 10592190A JP 10592190 A JP10592190 A JP 10592190A JP H045214 A JPH045214 A JP H045214A
- Authority
- JP
- Japan
- Prior art keywords
- base
- skin
- ascorbic acid
- drug
- external use
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 15
- 239000002537 cosmetic Substances 0.000 title claims abstract description 14
- 229940079593 drug Drugs 0.000 title claims abstract description 12
- 125000003289 ascorbyl group Chemical class [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 title abstract 2
- 208000017520 skin disease Diseases 0.000 claims abstract description 8
- 239000000839 emulsion Substances 0.000 claims abstract description 7
- -1 lipid peroxides Chemical class 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 230000009759 skin aging Effects 0.000 claims description 8
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 7
- 235000010323 ascorbic acid Nutrition 0.000 claims description 4
- 239000011668 ascorbic acid Substances 0.000 claims description 4
- 229960005070 ascorbic acid Drugs 0.000 claims description 4
- 150000000996 L-ascorbic acids Chemical class 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims 1
- 239000006071 cream Substances 0.000 abstract description 4
- 208000025865 Ulcer Diseases 0.000 abstract description 3
- 230000032683 aging Effects 0.000 abstract description 3
- 231100000397 ulcer Toxicity 0.000 abstract description 3
- 230000003628 erosive effect Effects 0.000 abstract description 2
- 206010048768 Dermatosis Diseases 0.000 abstract 2
- 238000009736 wetting Methods 0.000 abstract 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 230000000699 topical effect Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 239000002674 ointment Substances 0.000 description 4
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 4
- 201000004624 Dermatitis Diseases 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 235000019271 petrolatum Nutrition 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 235000020046 sherry Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 206010040943 Skin Ulcer Diseases 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 2
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 2
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 2
- 229960003415 propylparaben Drugs 0.000 description 2
- 231100000019 skin ulcer Toxicity 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 229940031439 squalene Drugs 0.000 description 2
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 239000003871 white petrolatum Substances 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N Glycerol trioctadecanoate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 101100248300 Mus musculus Rhbdf2 gene Proteins 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 206010040840 Skin erosion Diseases 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000007348 radical reaction Methods 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 150000003700 vitamin C derivatives Chemical class 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Landscapes
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
【発明の詳細な説明】
（産業上の利用分野）
本発明は、アスコルビン酸誘導体を含有する化粧品及び
外用薬に関する。更に詳しくは、アスコルビン酸誘導体
（ＡＡＤと略す〕を基剤に分散した、過剰のフリーラジ
カル、過酸化脂質が関与する皮膚疾患や皮膚の老化予防
等に用いる化粧品及び外用薬に関する。DETAILED DESCRIPTION OF THE INVENTION (Industrial Field of Application) The present invention relates to cosmetics and external medicines containing ascorbic acid derivatives. More specifically, the present invention relates to cosmetics and external medicines in which ascorbic acid derivatives (abbreviated as AAD) are dispersed in a base and are used to prevent skin diseases and skin aging associated with excess free radicals and lipid peroxides.
本発明の化粧品の対象は皮膚の老化予防等であり。The cosmetics of the present invention are intended to prevent skin aging.
外用薬の対象は皮膚面での潰瘍、びらん及び湿潤を伴う
皮膚病巣部である。The targets for topical medicine are skin lesions with ulcers, erosions, and moisture on the skin surface.
（従来技術と課題）
火傷、一般の外傷、難治性の皮膚潰瘍などで正常皮膚の
肉芽形成や、修復等の治癒傾向が得られないものに対し
て、画期的な外用薬が、また、最近の治験で皮膚の老化
にフリーラジカルを介した過酸化脂質の生成が関与して
いることが判明し、その機序を抑制することで女性の永
年の夢である皮膚の老化予防に役立つ化粧品の開発が強
く要望されている。八木らの報告によると、皮膚の火傷
部では、その障害により細胞膜が著しく破壊される。そ
の結果、細胞膜面に存在していた０鵞がｅｌｅｃｔｒｏ
ｎ ｔｒａｎｓｐｏｒｔを受け０．−に変化し、かつ細
胞膜表面に多量に存在していた不飽和脂肪酸にＯ８が反
応し多量の過酸化脂質を産生ずる。又、紫外線等の照射
によりラジカル反応の結果皮膚の老化が除々に進んでい
く、過剰に産生された過酸化脂質は、活性酸素と同様に
生体の各組織に強い障害破壊を与える事が知られており
、この受傷部皮膚で大量に産生された過酸化脂質は、火
傷を受けた以上に受傷部の皮膚組織を破壊し、火傷の傷
の悪化を促進するといわれている。この火傷時に見られ
る現象は、火傷に限らず、一般の外傷部、手術後の傷口
にも起こっており、多量に産生された過酸化脂質は傷口
で外傷やメスで受けた傷以上に傷口の拡大、悪化を促進
している。円側らは、このような治癒傾向の遅い皮膚潰
瘍の持続する患者では、上記のような原因で過酸化脂質
が異常にその皮膚に増加し、病巣部の過酸化脂質を消去
するために生体に存在しているＳＯＤ酵素が低下してい
る事を報告している。又、日常の紫外線照射が長期にわ
たれば過酸化脂質による皮膚の老化の原因と考えられて
いる。皮膚疾患で接触性皮膚炎、日光性皮膚炎、アトピ
ー性皮膚炎、主婦湿疹などのうち、一般の治療に抵抗し
、難治性で激しい皮膚炎症が持続し、皮膚のびらん、更
に潰瘍を招いている患者の病巣部のみならず、皮膚のシ
ミ等の老化現象に過酸化脂質が関与しており、その結果
、本発明の化粧品、外用薬が治療効果をもたらすのであ
る。(Prior Art and Issues) An innovative topical drug is available for treating burns, general trauma, intractable skin ulcers, etc. that do not show normal skin granulation formation or healing tendencies such as repair. Recent clinical trials have revealed that the generation of lipid peroxide through free radicals is involved in skin aging, and by suppressing this mechanism, cosmetics can help prevent skin aging, which is a long-held dream of women. There is a strong demand for the development of According to a report by Yagi et al., cell membranes are significantly destroyed in burnt areas of the skin due to this damage. As a result, the zero cells that were present on the cell membrane surface became electro
n transport received 0. -, and O8 reacts with the unsaturated fatty acids that were present in large quantities on the cell membrane surface, producing a large amount of lipid peroxide. In addition, excessively produced lipid peroxides, which gradually progress skin aging as a result of radical reactions caused by irradiation with ultraviolet rays, etc., are known to cause strong damage and destruction to various tissues of the living body, similar to active oxygen. It is said that the lipid peroxide produced in large quantities in the skin of the injured area destroys the skin tissue of the injured area more than that caused by a burn, and accelerates the deterioration of the burn wound. This phenomenon observed during burns is not limited to burns, but also occurs in general trauma areas and wounds after surgery. It is promoting expansion and deterioration. Engai et al. reported that in patients with persistent skin ulcers that tend to heal slowly, lipid peroxide increases abnormally in the skin due to the causes mentioned above, and the body needs to treat lipid peroxide in the lesion to eliminate the lipid peroxide. It has been reported that the SOD enzyme present in Furthermore, prolonged daily exposure to ultraviolet rays is thought to cause skin aging due to lipid peroxide. Skin diseases such as contact dermatitis, sun-induced dermatitis, atopic dermatitis, and housewife's eczema are resistant to conventional treatments, resulting in persistent, intractable and severe skin inflammation, leading to skin erosion and even ulcers. Lipid peroxides are involved not only in lesions of patients but also in aging phenomena such as age spots on the skin, and as a result, the cosmetics and topical drugs of the present invention have therapeutic effects.
特公昭５９−１０３２４号公報及び特開昭５５−８７７
１２号にスーパーオキシジスムターゼ（ＳＯＤ）が皮膚
や毛髪にたいし美容上の効果を有することが開示され、
更に公表特許公報昭６２−５０１０７２号に一般の皮膚
疾患に対するＳＯＤの効果が開示されている。ＳＯＤは
０トのみを消去する酵素であるが、本発明のＡＡＤは広
くフリーラジカルを消去し、過酸化脂質の生成を抑制す
ることが知られている１本発明の化粧品並びに外用薬は
皮膚に対する害もなく、一般の皮膚疾患の治療や美容上
の効果を目的とするものである。Japanese Patent Publication No. 59-10324 and Japanese Patent Publication No. 55-877
No. 12 discloses that superoxydismutase (SOD) has cosmetic effects on skin and hair,
Furthermore, the effect of SOD on common skin diseases is disclosed in Japanese Patent Publication No. 62-501072. SOD is an enzyme that only scavenges free radicals, but the AAD of the present invention is widely known to scavenge free radicals and suppress the production of lipid peroxides. It is harmless and is intended for the treatment of common skin diseases and for cosmetic effects.
（発明の構成と効果）
本発明の要旨は、本願特許請求の範囲の第１項に記載の
通りであって、ＡＡＤを基剤に分散した、過剰の過酸化
脂質が関与する皮膚疾患に有効で、皮膚の老化予防に役
立つ物質である。なお、上記の基剤とは乳剤（０／Ｗ）
、軟膏（Ｗｌｏ）、シェリー等であって、ＡＡＤの分散
系を意味する。(Structure and Effects of the Invention) The gist of the present invention is as described in item 1 of the claims of the present application, and is effective for treating skin diseases associated with excessive lipid peroxide, in which AAD is dispersed in a base. It is a substance that helps prevent skin aging. Note that the above base is an emulsion (0/W)
, ointment (Wlo), sherry, etc., and refers to a dispersion of AAD.
（ＡＡＤの製法）
ＡＡＤはビタミンＣの誘導体で、フリーラジカルから生
体を保護する役割りを果たす皮膚の老化予防物質である
。その作用はフリーラジカルを不均化する反応：Ｒ＋Ａ
ＡＤ−ＡＡＤ ＋ＲＨ−（ＡＡＤ−Ｈ＋ＲＨｏｒ Ａ
ＡＤ−ＡＡＤ＋ＲＨ）を触媒するといわれている。具体
的なＡＡＤとしては２−ｏｃｔａｄｅｃｙｌ ａｓｃｏ
ｒｂｉｃ ａｃｉｄが公知である。(Production method of AAD) AAD is a derivative of vitamin C, and is a skin anti-aging substance that plays a role in protecting living bodies from free radicals. Its action is a reaction that disproportionates free radicals: R+A
AD-AAD +RH-(AAD-H+RHor A
It is said to catalyze AD-AAD+RH). A specific AAD is 2-octadecyl asco
rbic acid is known.
ＡＡＤは分子量４２６の物質であって、精製手段なども
公知である。ＡＡＤの種類としてはＡｌｋｙｌ基の１０
〜１８個ついたものであればほぼ同一の効果を示す０本
外用薬を臨床に使用するには、通常は上記ＡＡＤを基剤
に分散して局所に塗布して用いる。これらの基剤として
は乳剤（０／Ｗ）が好ましい、ＡＡＤを分散したものを
患部に塗布または化粧品として使用すれば過酸化脂質の
生成を抑え、かつ油分により外界から保護され効果があ
と推定される。AAD is a substance with a molecular weight of 426, and purification means are also known. The types of AAD are Alkyl group 10
For clinical use of topical drugs, the AAD is usually dispersed in a base and applied topically. Emulsions (0/W) are preferred as these bases.If AAD dispersed is applied to the affected area or used as a cosmetic, it will suppress the production of lipid peroxide, and the oil will protect it from the outside world and its effects will be expected later. Ru.
参考例（基剤及びＡＡＤ外用薬の調製法）（１）クリー
ム基剤（０／Ｗ型）
本発明の外用薬に使用する基剤としては、ｍｊ述の乳剤
（０／Ｗ型）であるクリーム基剤が適している。このク
リーム基剤とはＯ／Ｗ型の乳剤であって、水分の含量が
基剤に対して７０重量％未満のエマルジョンで、好まし
くは水分が４０〜５０重量％のものが望ましい、この望
ましいクリーム基剤の処方の一例は、下記の通りである
。Reference example (base and preparation method of AAD external medicine) (1) Cream base (0/W type) The base used in the external medicine of the present invention is the emulsion (0/W type) described in mj. A cream base is suitable. This cream base is an O/W type emulsion with a water content of less than 70% by weight based on the base, preferably an emulsion with a water content of 40 to 50% by weight. An example of the formulation of the base is as follows.
処方 １００ｇ中の各成分
スクワレン ２２．２ｇ白色ワセリン
１３．９ｇステアリルアルコール １
２．２ｇプロピレングリコール ６．７ｇラウリ
ル硫酸ナトリウム １．１ｇエチルパラベン
０．０２ｇプロピルパラベン ０．
０２ｇ水
４３． ８６ｇ上記の基剤を調製するには次の
ように実施する７油性基剤（スクワレン、白色ワセリン
、ステアリンアルコール）を水浴上（約１００℃）で過
熱溶解する。又、水性基剤（プロピレングリコール、ラ
ウリル硫酸ナトリウム、エチルパラベン、プロピルパラ
ベン、水）を水浴上（約１００℃）で過熱溶解後、既に
溶解済の油性基剤中に加え乳化した後、撹拌を行いなが
ら冷却して基剤とする。なお、上記の基剤から本発明の
各種ＡＡＤ外用薬を調製するには、ＡＡＤ粉末１００ｍ
ｇを少量の水（１〜２ｍ１）に分散後１００ｇの上記基
剤に加え充分混合する。Prescription Each component squalene in 100g 22.2g white petrolatum
13.9g stearyl alcohol 1
2.2g Propylene Glycol 6.7g Sodium Lauryl Sulfate 1.1g Ethylparaben
0.02g Propylparaben 0.
02g water
43. 86g To prepare the above base, proceed as follows. 7. Dissolve the oil base (squalene, white petrolatum, stearin alcohol) under heating on a water bath (about 100°C). Also, after heating and dissolving the aqueous base (propylene glycol, sodium lauryl sulfate, ethyl paraben, propyl paraben, water) on a water bath (approximately 100°C), add it to the already dissolved oil base to emulsify, and then stir. While processing, cool and use as a base. In addition, in order to prepare various AAD topical drugs of the present invention from the above-mentioned base, 100 m of AAD powder is required.
g in a small amount of water (1-2 ml), then added to 100 g of the above base and mixed thoroughly.
（２）軟膏
処方の具体例としては、１０局の黄色軟膏（脱水ラノリ
ン５０重量部、黄ロウ５０重量部、黄色ワセリン９００
重１１がある０本発明のＷ２Ｏ型のＡＡＤ外用薬は、Ａ
ＡＤ粉末１００ｍｇを５ｍｌの水に分散せしめ、これを
９５ｇの上記黄色軟膏とよく練合わせて製造する。(2) Specific examples of ointment prescriptions include 10 yellow ointments (50 parts by weight of dehydrated lanolin, 50 parts by weight of yellow wax, 900 parts by weight of yellow petrolatum).
The W2O type AAD topical drug of the present invention has A
100 mg of AD powder is dispersed in 5 ml of water, and this is thoroughly kneaded with 95 g of the yellow ointment described above.
（３）Ｇｅ ｌ剤
この基剤は所謂シェリーであって、多量の水分を含む基
剤である。具体例としては、歯品名カルボボール９３４
というポリアクリル酸ナトリウムを約０５重量％水に分
散させて粘度の高いシェリーが得られる５本発明のＡＡ
ＤＧｅ Ｉ剤は、こ（７）Ｇｅｌ剤１００ ｇ ニＡ
Ａ Ｄ粉末１００ｍｇを均に分数させたものである。(3) Gel agent This base is so-called sherry and contains a large amount of water. A specific example is the tooth product name Carbo Ball 934.
5 AA of the present invention, in which a highly viscous sherry can be obtained by dispersing sodium polyacrylate in water at about 0.05% by weight.
The DGe I agent is (7) Gel agent 100 g NiA
100 mg of AD powder was evenly divided into fractions.
Claims (1)
ｙｌａｓｃｏｒｂｉｃ ａｃｉｄなどを基剤に分散した
、過剰のフリーラジカル、過酸化脂質が関与する皮膚疾
患や皮膚の老化予防等に有効なアスコルビン酸を含む化
粧品及び外用薬 ２、基剤が水分７０重量％未満のｏｉｌ ｉｎ ｗａｔ
ｅｒ型の乳剤である特許請求の範囲第１項記載のアスコ
ルビン酸誘導体を含む化粧品及び外用剤 ３、基剤が水分４０重量％乃至５０重量％である特許請
求の範囲第１項記載のアスコルビン酸誘導体を含む化粧
品及び外用剤[Claims] 1. 2-octadec derived from ascorbic acid
Cosmetics and external medicines containing ascorbic acid, which is effective for preventing skin diseases and skin aging caused by excessive free radicals and lipid peroxides, dispersed in a base such as ylascorbic acid, with a base water content of less than 70% by weight. oil in wat
Cosmetics and external preparations 3 containing ascorbic acid derivatives according to claim 1, which are er-type emulsions, and ascorbic acid according to claim 1, whose base has a water content of 40% to 50% by weight. Cosmetics and external preparations containing derivatives
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP10592190A JPH045214A (en) | 1990-04-21 | 1990-04-21 | Cosmetic and drug for external use containing ascorbic acid derivative |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP10592190A JPH045214A (en) | 1990-04-21 | 1990-04-21 | Cosmetic and drug for external use containing ascorbic acid derivative |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH045214A true JPH045214A (en) | 1992-01-09 |
Family
ID=14420332
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP10592190A Pending JPH045214A (en) | 1990-04-21 | 1990-04-21 | Cosmetic and drug for external use containing ascorbic acid derivative |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH045214A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2123272A4 (en) * | 2007-01-26 | 2010-04-21 | Shiseido Co Ltd | Adam inhibitor |
-
1990
- 1990-04-21 JP JP10592190A patent/JPH045214A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2123272A4 (en) * | 2007-01-26 | 2010-04-21 | Shiseido Co Ltd | Adam inhibitor |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4010574B2 (en) | Topical skin preparation | |
| US5952383A (en) | Pharmaceutical composition for oral delivery | |
| JP3506701B2 (en) | Wound healing composition, its preparation and use | |
| EP0414605A1 (en) | Pasty aqueous pharmaceutical compositions | |
| JP4564471B2 (en) | Composition suitable for external use | |
| CA1150631A (en) | Agent for preventing or treating psoriasis | |
| JP2003502071A (en) | Fish serine proteinases and their use in medicines and cosmetics | |
| JPS60100517A (en) | Radiation remedy for ulcer and method | |
| USRE33107E (en) | Compositions containing 1α-hydroxycholecalciferol for topical treatment of skin disorders and methods employing same | |
| EP0055635A1 (en) | Pharmaceutical composition with acetylsalicylic acid in gel form | |
| US6541517B1 (en) | Treatment of skin disorders | |
| JPS62501072A (en) | Method of preventing or reducing skin irritation using formulations containing superoxide dismutase | |
| JPH053454B2 (en) | ||
| CA1112164A (en) | Therapeutic selenium compositions and the use thereof | |
| JPH045214A (en) | Cosmetic and drug for external use containing ascorbic acid derivative | |
| RU2233152C1 (en) | Anti-inflammatory and anti-itching cream for treatment of dermatological disease | |
| EP0747040A1 (en) | Petroleum jelly with inositol phosphates | |
| JPH04346936A (en) | Collagen metabolism activator | |
| JP2001322990A (en) | Active oxygen scavenger and composition containing the same for erasing active oxygen | |
| JPH09143067A (en) | Therapeutic agent for atopic dermatitis | |
| US5977176A (en) | Compositions for the treatment of warts and herpes | |
| JPH04334321A (en) | Preventive for dermatic inflammation | |
| JPH0259519A (en) | Remedy for skin inflammation | |
| EP0252033B1 (en) | A "gel" pharmaceutical form containing n-(2.6-dichloro-m-tolil)-anthranilic acid (mechlophenamic acid) for use in therapy by topical application | |
| JPH08208498A (en) | Dermal preparation composition for external use |